← Human Trials & Peer-Reviewed Studies
A prospective and randomized study comparing the use of alarms, desmopressin and imipramine in the treatment of monosymptomatic nocturnal enuresis
Plain-language guide to PMID 36717289 (2023): randomized controlled trial study of Vasopressin and Desmopressin.
Key Facts
- PMID
- 36717289
- Journal
- Journal of pediatric urology
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Mello MF et al. (7 authors)
- DOI
- 10.1016/j.jpurol.2023.01.004
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vasopressin and Desmopressin, published as a randomized controlled trial.
The treatment of MNE can be performed through behavioral therapy, use of alarms or medications such as desmopressin and imipramine.
Age between 5 and 16 years old, with MNE, evaluated at the pediatric urology outpatient clinic of Hospital Infantil Menino Jesus.
Who Took Part
By PubMed's age tags, the people studied were young children, children and teenagers, both men and women.
Those partial responders or non-responders received a patient ID and were randomized to four groups: Alarm Group (G1), Desmopressin Group - DDAVP (G2), Imipramine Group (G3) and Control (G4).
How the Study Was Run
In design terms this was a randomized study.
Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Prospective and randomized study comparing different intervention and a control group (receiving only behavior therapy) for MNE.
What Was Measured
Age between 5 and 16 years old, with MNE, evaluated at the pediatric urology outpatient clinic of Hospital Infantil Menino Jesus.
After 6 months, the children were reevaluated for MNE.
PubMed files the paper under topics including Nocturnal Enuresis, Deamino Arginine Vasopressin, Imipramine and Enuresis.
Author keywords: Alarms, Children, Desmopressin and Monosymptomatic nocturnal enuresis.
What This Means in Plain Language
The paper is a randomized study of Vasopressin and Desmopressin.
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2023 (Journal of pediatric urology), a journal based in England.
More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.
Our Notes on the Compounds
Vasopressin: A 9-amino-acid hormone (antidiuretic hormone) that controls water balance and blood vessel tone; used in septic shock.
Desmopressin: A synthetic vasopressin analog (DDAVP) used for bedwetting, diabetes insipidus and some bleeding disorders.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.